University Of California, San Francisco

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

Invivyd has established the SPEAR Study Group with leading researchers to investigate monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome, following anecdotal reports of symptom relief with PEMGARDA.

A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.

A retrospective analysis by Mass General Brigham and UCSF researchers found that glioblastoma patients taking gabapentin lived 4-6 months longer than those who didn't receive the medication.

The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.

A new JAMA Network Open study reveals that while most OB/GYNs didn't immediately leave states with abortion bans after the 2022 Dobbs ruling, a significant decline is now occurring in the 12 most restrictive states.

New research shows that complete blood count (CBC) tests can identify or predict multiple diseases including heart problems, type 2 diabetes, osteoporosis, and kidney disease by analyzing individual "set points" in blood components.

FG-3246, a first-in-class antibody-drug conjugate targeting CD46, demonstrated an 80% disease control rate and 20% objective response rate in heavily pre-treated metastatic castration-resistant prostate cancer patients.

Glucotrack successfully completed its first-in-human clinical study of a continuous blood glucose monitor implanted in the subclavian vein, with no serious adverse events reported.

The University of California, San Francisco has secured a $75.4 million grant from the National Institute on Aging to conduct a groundbreaking platform trial testing multiple drugs for progressive supranuclear palsy.